These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 27776644)

  • 1. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.
    Ruhlmann V; Ruhlmann M; Bellendorf A; Grueneisen J; Sawicki LM; Grafe H; Forsting M; Bockisch A; Umutlu L
    Eur J Radiol; 2016 Nov; 85(11):1941-1947. PubMed ID: 27776644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.
    Grueneisen J; Sawicki LM; Wetter A; Kirchner J; Kinner S; Aktas B; Forsting M; Ruhlmann V; Umutlu L
    Eur J Radiol; 2017 Apr; 89():14-19. PubMed ID: 28267530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI.
    Beiderwellen K; Gomez B; Buchbender C; Hartung V; Poeppel TD; Nensa F; Kuehl H; Bockisch A; Lauenstein TC
    Eur J Radiol; 2013 Nov; 82(11):e669-75. PubMed ID: 24011443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results.
    Beiderwellen K; Grueneisen J; Ruhlmann V; Buderath P; Aktas B; Heusch P; Kraff O; Forsting M; Lauenstein TC; Umutlu L
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):56-65. PubMed ID: 25223420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT.
    Kirchner J; Sawicki LM; Suntharalingam S; Grueneisen J; Ruhlmann V; Aktas B; Deuschl C; Herrmann K; Antoch G; Forsting M; Umutlu L
    PLoS One; 2017; 12(2):e0172553. PubMed ID: 28225831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.
    Schaarschmidt BM; Buchbender C; Nensa F; Grueneisen J; Gomez B; Köhler J; Reis H; Ruhlmann V; Umutlu L; Heusch P
    PLoS One; 2015; 10(1):e0116277. PubMed ID: 25574968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
    Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
    Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body [¹⁸F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results.
    Beiderwellen K; Huebner M; Heusch P; Grueneisen J; Ruhlmann V; Nensa F; Kuehl H; Umutlu L; Rosenbaum-Krumme S; Lauenstein TC
    Eur Radiol; 2014 Aug; 24(8):2023-30. PubMed ID: 24907940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer.
    Vrachimis A; Burg MC; Wenning C; Allkemper T; Weckesser M; Schäfers M; Stegger L
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):212-220. PubMed ID: 26419851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma.
    Ponisio MR; McConathy J; Laforest R; Khanna G
    Pediatr Radiol; 2016 Aug; 46(9):1258-68. PubMed ID: 27003132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT.
    Samarin A; Hüllner M; Queiroz MA; Stolzmann P; Burger IA; von Schulthess G; Veit-Haibach P
    Nucl Med Commun; 2015 Dec; 36(12):1165-73. PubMed ID: 26397999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies.
    Grueneisen J; Schaarschmidt BM; Beiderwellen K; Schulze-Hagen A; Heubner M; Kinner S; Forsting M; Lauenstein T; Ruhlmann V; Umutlu L
    J Nucl Med; 2014 Dec; 55(12):1930-5. PubMed ID: 25453042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
    Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
    Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
    Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ
    J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.